Amelia Louise Sattler, MD
Family Practice · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Sattler’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A119692 · Current
Licensed to practise in California · since 2012 · expires 2027-12-31 · Mayo Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$15,330
Medicare paid this office $15,330 for 79 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 21 | $2,984 | $77 |
| Short return visit (20+ min) | 27 | $2,745 | $57 |
| Return visit (30+ min) | 30 | $1,989 | $60 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 24 | $1,611 | $67 |
| Long return visit (40+ min) | 14 | $1,257 | $90 |
See all 8 services
| Return visit (30+ min) | 21 | $2,984 | $77 |
| Short return visit (20+ min) | 27 | $2,745 | $57 |
| Return visit (30+ min) | 30 | $1,989 | $60 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 24 | $1,611 | $67 |
| Long return visit (40+ min) | 14 | $1,257 | $90 |
| Short return visit (20+ min) | 12 | $848 | $47 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 20 | $524 | $15 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 12 | $195 | $15 |
Who their Medicare patients are
79 Original Medicare patients in 2024. Average age 69 · Under 65 24% · Women 70% · Also on Medicaid 34% · Health risk score 1.54. Above the middle of the specialty; the typical family practice clinician is at 1.13.
Conditions among them: High blood pressure 66% · Diabetes 32% · Depression 25% · Chronic kidney disease 20% · Coronary heart disease 18% · Atrial fibrillation 16% · Heart failure 14% · COPD 14%.
The office billed $111,681, Medicare allowed $21,767 and paid $15,330; for 268 services of 16 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 79 | 268 | 69 | 1.54 | $111,681 | $15,330 |
| 2023 | 66 | 180 | 69 | 1.82 | $81,901 | $10,880 |
| 2022 | 68 | 200 | 70 | 1.30 | $90,773 | $11,566 |
| 2021 | 67 | 201 | 69 | 1.44 | $93,779 | $12,365 |
| 2020 | 56 | 162 | 69 | 1.30 | $47,522 | $11,028 |
| 2019 | 62 | 128 | 67 | 1.79 | $20,176 | $9,577 |
| 2018 | 73 | 163 | 70 | 1.48 | $30,943 | $12,417 |
| 2017 | 53 | 88 | 67 | 1.47 | $19,393 | $5,442 |
| 2016 | 71 | 142 | 68 | 1.33 | $29,629 | $9,660 |
| 2015 | 71 | 138 | 69 | 1.76 | $30,155 | $9,544 |
| 2014 | 61 | 90 | 67 | 1.29 | $18,244 | $5,730 |
| 2013 | 16 | 17 | 70 | 1.61 | $3,363 | $1,178 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Return visit (30+ min) | 31 | $3,587 | $55 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 34 | $2,077 | $61 |
| Long return visit (40+ min) | 15 | $1,442 | $76 |
| Short return visit (20+ min) | 19 | $1,379 | $49 |
2022: 6 services
| Return visit (30+ min) | 30 | $3,287 | $50 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | $2,217 | $89 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 29 | $1,850 | $64 |
| Short return visit (20+ min) | 20 | $1,795 | $50 |
| Telephone medical discussion with physician, 11-20 minutes | 15 | $1,186 | $56 |
| Long return visit (40+ min) | 11 | $779 | $60 |
2021: 3 services
| Return visit (30+ min) | 40 | $5,486 | $57 |
| Short return visit (20+ min) | 27 | $1,992 | $52 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 22 | $1,425 | $65 |
2020: 2 services
| Return visit (30+ min) | 43 | $5,292 | $69 |
| Short return visit (20+ min) | 13 | $853 | $43 |
2019: 2 services
| Return visit (30+ min) | 47 | $5,969 | $66 |
| Long return visit (40+ min) | 12 | $1,413 | $94 |
2018: 3 services
| Return visit (30+ min) | 44 | $4,874 | $57 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 16 | $2,246 | $140 |
| Return visit (30+ min) | 24 | $2,119 | $71 |
2017: 1 service
| Return visit (30+ min) | 41 | $3,722 | $57 |
2016: 3 services
| Return visit (30+ min) | 53 | $6,794 | $67 |
| Long return visit (40+ min) | 12 | $991 | $83 |
| Short return visit (20+ min) | 13 | $631 | $37 |
2015: 2 services
| Return visit (30+ min) | 40 | $4,207 | $65 |
| Short return visit (20+ min) | 23 | $1,320 | $40 |
2014: 2 services
| Return visit (30+ min) | 24 | $2,307 | $66 |
| Short return visit (20+ min) | 27 | $1,183 | $42 |
2013: 1 service
| Return visit (30+ min) | 12 | $879 | $68 |
Medicaid work
$369 in 2022
Medicaid paid $369 for 27 billed services this clinician did in 2022, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 27 | $369 |
| 2022 | 27 | 1 | 14 | $369 |
Drugs they prescribed that Part D paid
$80,522
Pharmacies billed $80,522 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 11% of their Part D prescriptions (112 of 1,044) in 2024. A higher opioid share than 9 in 10 peers; the typical family practice clinician is at 2%. Long-acting opioids: 19% of their opioid prescriptions.
945 generic and fewer than 11 brand-name prescriptions · $80,522 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ondansetron Odt | 17 | $1,492 | $88 |
| Hydrocodone-Acetaminophen | 37 | $1,368 | $37 |
| Gabapentin | 29 | $1,178 | $41 |
| Levothyroxine | 31 | $950 | $31 |
| Pregabalin | 16 | $506 | $32 |
See all 29 drugs
| Ondansetron Odt | 17 | $1,492 | $88 |
| Hydrocodone-Acetaminophen | 37 | $1,368 | $37 |
| Gabapentin | 29 | $1,178 | $41 |
| Levothyroxine | 31 | $950 | $31 |
| Pregabalin | 16 | $506 | $32 |
| Atorvastatin | 54 | $447 | $8 |
| Amlodipine Besylate | 34 | $426 | $13 |
| Pravastatin | 20 | $419 | $21 |
| Losartan-Hydrochlorothiazide | 24 | $400 | $17 |
| Rosuvastatin | 15 | $398 | $27 |
| Omeprazole | 31 | $358 | $12 |
| Losartan | 34 | $311 | $9 |
| Alendronate | 19 | $276 | $15 |
| Promethazine | 14 | $240 | $17 |
| Fluticasone Propionate | 17 | $216 | $13 |
| Oxycodone | 32 | $215 | $7 |
| Pantoprazole | 38 | $212 | $6 |
| Metformin Hcl Er | 16 | $206 | $13 |
| Escitalopram | 19 | $162 | $9 |
| Metformin | 11 | $114 | $10 |
| Trazodone | 13 | $93 | $7 |
| Tamsulosin | 13 | $72 | $6 |
| Finasteride | 11 | $59 | $5 |
| Lorazepam | 25 | $53 | $2 |
| Ibuprofen | 12 | $52 | $4 |
| Diazepam | 14 | $51 | $4 |
| Hydromorphone | 13 | $45 | $3 |
| Hydrochlorothiazide | 15 | $15 | $1 |
| Atenolol | 16 | $13 | $1 |
Year by year
| 2024 | 1,044 | 74 | 11% (112) | None | $80,522 |
| 2023 | 960 | 74 | 8% (74) | None | $92,354 |
| 2022 | 1,069 | 83 | 5% (58) | None | $77,665 |
| 2021 | 1,009 | 87 | 5% (54) | None | $63,827 |
| 2020 | 1,028 | 85 | 6% (64) | None | $47,930 |
| 2019 | 1,048 | 100 | 5% (49) | None | $69,216 |
| 2018 | 1,001 | 94 | 5% (51) | None | $79,891 |
| 2017 | 1,345 | 115 | 3% (44) | 21% | $92,568 |
| 2016 | 1,210 | 149 | 7% (82) | None | $63,742 |
| 2015 | 607 | 76 | 12% (73) | None | $43,163 |
| 2014 | 367 | 71 | 9% (34) | None | $20,443 |
| 2013 | 491 | 85 | 10% (49) | None | $23,498 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 25 drugs
| Pregabalin | 21 | $1,418 | $68 |
| Atorvastatin | 50 | $1,325 | $27 |
| Hydrocodone-Acetaminophen | 26 | $1,088 | $42 |
| Rosuvastatin | 18 | $813 | $45 |
| Losartan | 25 | $776 | $31 |
| Amlodipine Besylate | 31 | $706 | $23 |
| Albuterol Sulfate Hfa | 13 | $673 | $52 |
| Pantoprazole | 26 | $483 | $19 |
| Ondansetron Odt | 16 | $455 | $28 |
| Omeprazole | 27 | $437 | $16 |
| Levothyroxine | 31 | $373 | $12 |
| Gabapentin | 23 | $368 | $16 |
| Fluticasone Propionate | 11 | $327 | $30 |
| Oxycodone | 26 | $252 | $10 |
| Alendronate | 16 | $235 | $15 |
| Pravastatin | 15 | $227 | $15 |
| Escitalopram | 13 | $216 | $17 |
| Atenolol | 14 | $194 | $14 |
| Hydrochlorothiazide | 26 | $192 | $7 |
| Diazepam | 17 | $177 | $10 |
| Lorazepam | 27 | $155 | $6 |
| Metformin | 15 | $147 | $10 |
| Trazodone | 12 | $127 | $11 |
| Citalopram Hbr | 12 | $124 | $10 |
| Hydromorphone | 12 | $49 | $4 |
2022: 32 drugs
| Gabapentin | 36 | $1,222 | $34 |
| Hydrocodone-Acetaminophen | 25 | $1,113 | $45 |
| Pregabalin | 15 | $1,066 | $71 |
| Atorvastatin | 60 | $892 | $15 |
| Clindamycin Phosphate | 12 | $818 | $68 |
| Diclofenac | 22 | $805 | $37 |
| Omeprazole | 35 | $598 | $17 |
| Methocarbamol | 13 | $588 | $45 |
| Albuterol Sulfate Hfa | 12 | $580 | $48 |
| Pravastatin | 20 | $504 | $25 |
| Trazodone | 15 | $364 | $24 |
| Escitalopram | 14 | $353 | $25 |
| Levothyroxine | 18 | $351 | $20 |
| Tamsulosin | 18 | $319 | $18 |
| Amlodipine Besylate | 29 | $313 | $11 |
| Montelukast | 15 | $307 | $20 |
| Pantoprazole | 21 | $293 | $14 |
| Metformin | 20 | $274 | $14 |
| Losartan | 29 | $246 | $8 |
| Cyclobenzaprine | 12 | $238 | $20 |
| Ondansetron Odt | 13 | $237 | $18 |
| Oxycodone | 21 | $236 | $11 |
| Fluticasone Propionate | 16 | $231 | $14 |
| Furosemide | 12 | $223 | $19 |
| Simvastatin | 16 | $200 | $12 |
| Hydrochlorothiazide | 34 | $199 | $6 |
| Sertraline | 13 | $196 | $15 |
| Finasteride | 18 | $184 | $10 |
| Lorazepam | 28 | $134 | $5 |
| Atenolol | 13 | $115 | $9 |
| Fluconazole | 11 | $78 | $7 |
| Hydrocortisone | 11 | $47 | $4 |
2021: 33 drugs
| Eliquis | 12 | $7,067 | $589 |
| Albuterol Sulfate Hfa | 38 | $2,105 | $55 |
| Gabapentin | 21 | $1,591 | $76 |
| Bupropion Xl | 11 | $1,116 | $101 |
| Hydrocodone-Acetaminophen | 23 | $1,061 | $46 |
| Atorvastatin | 44 | $1,026 | $23 |
| Baclofen | 14 | $938 | $67 |
| Fluocinonide | 11 | $920 | $84 |
| Diclofenac | 24 | $837 | $35 |
| Levothyroxine | 34 | $768 | $23 |
| Ventolin Hfa | 13 | $763 | $59 |
| Pregabalin | 16 | $748 | $47 |
| Escitalopram | 22 | $523 | $24 |
| Omeprazole | 33 | $498 | $15 |
| Fluticasone Propionate | 19 | $396 | $21 |
| Tamsulosin | 23 | $359 | $16 |
| Pravastatin | 18 | $334 | $19 |
| Montelukast | 18 | $286 | $16 |
| Rosuvastatin | 12 | $279 | $23 |
| Metformin | 20 | $259 | $13 |
| Pantoprazole | 19 | $258 | $14 |
| Amlodipine Besylate | 33 | $242 | $7 |
| Lisinopril | 17 | $193 | $11 |
| Simvastatin | 17 | $190 | $11 |
| Furosemide | 13 | $167 | $13 |
| Hydrochlorothiazide | 40 | $157 | $4 |
| Finasteride | 11 | $153 | $14 |
| Glipizide | 12 | $135 | $11 |
| Ibuprofen | 12 | $128 | $11 |
| Sertraline | 12 | $128 | $11 |
| Oxycodone | 12 | $120 | $10 |
| Lorazepam | 29 | $111 | $4 |
| Losartan | 17 | $111 | $7 |
2020: 25 drugs
| Gabapentin | 26 | $1,308 | $50 |
| Pregabalin | 18 | $1,160 | $64 |
| Fluocinonide | 15 | $979 | $65 |
| Levothyroxine | 41 | $976 | $24 |
| Albuterol Sulfate Hfa | 17 | $809 | $48 |
| Atorvastatin | 46 | $778 | $17 |
| Hydrocodone-Acetaminophen | 34 | $735 | $22 |
| Pravastatin | 18 | $602 | $33 |
| Escitalopram | 23 | $566 | $25 |
| Fluticasone Propionate | 22 | $499 | $23 |
| Amlodipine Besylate | 37 | $380 | $10 |
| Omeprazole | 33 | $374 | $11 |
| Tamsulosin | 23 | $364 | $16 |
| Diclofenac | 13 | $356 | $27 |
| Losartan | 28 | $232 | $8 |
| Hydroxyzine | 12 | $197 | $16 |
| Fluconazole | 14 | $173 | $12 |
| Hydrochlorothiazide | 39 | $167 | $4 |
| Metformin | 17 | $164 | $10 |
| Simvastatin | 17 | $164 | $10 |
| Ibuprofen | 20 | $153 | $8 |
| Montelukast | 18 | $145 | $8 |
| Lisinopril | 17 | $140 | $8 |
| Lorazepam | 22 | $126 | $6 |
| Pantoprazole | 20 | $125 | $6 |
2019: 28 drugs
| Lyrica | 12 | $7,850 | $654 |
| Olopatadine | 22 | $4,636 | $211 |
| Clonidine | 11 | $1,751 | $159 |
| Ventolin Hfa | 20 | $1,748 | $87 |
| Atorvastatin | 57 | $1,183 | $21 |
| Levothyroxine | 45 | $1,085 | $24 |
| Gabapentin | 29 | $1,006 | $35 |
| Hydrocodone-Acetaminophen | 34 | $742 | $22 |
| Escitalopram | 20 | $591 | $30 |
| Montelukast | 18 | $502 | $28 |
| Omeprazole | 32 | $459 | $14 |
| Pravastatin | 25 | $398 | $16 |
| Amlodipine Besylate | 52 | $396 | $8 |
| Losartan | 27 | $364 | $13 |
| Ranitidine | 20 | $352 | $18 |
| Tamsulosin | 14 | $343 | $25 |
| Glipizide | 15 | $322 | $21 |
| Metformin | 22 | $278 | $13 |
| Fluticasone Propionate | 22 | $226 | $10 |
| Lisinopril | 16 | $213 | $13 |
| Hydrochlorothiazide | 38 | $201 | $5 |
| Baclofen | 12 | $149 | $12 |
| Ibuprofen | 21 | $145 | $7 |
| Pantoprazole | 23 | $145 | $6 |
| Simvastatin | 13 | $84 | $6 |
| Naproxen | 11 | $78 | $7 |
| Atenolol | 16 | $67 | $4 |
| Lorazepam | 12 | $34 | $3 |
2018: 19 drugs
| Lyrica | 17 | $18,279 | $1,075 |
| Gabapentin | 41 | $1,189 | $29 |
| Ventolin Hfa | 16 | $991 | $62 |
| Levothyroxine | 43 | $843 | $20 |
| Hydrocodone-Acetaminophen | 37 | $820 | $22 |
| Atorvastatin | 53 | $702 | $13 |
| Pravastatin | 23 | $514 | $22 |
| Fluticasone Propionate | 37 | $465 | $13 |
| Amlodipine Besylate | 57 | $377 | $7 |
| Metformin | 22 | $335 | $15 |
| Ranitidine | 14 | $277 | $20 |
| Losartan | 27 | $231 | $9 |
| Tamsulosin | 15 | $205 | $14 |
| Hydrochlorothiazide | 32 | $191 | $6 |
| Omeprazole | 18 | $162 | $9 |
| Simvastatin | 14 | $147 | $10 |
| Fluoxetine | 11 | $102 | $9 |
| Zolpidem | 11 | $97 | $9 |
| Atenolol | 17 | $95 | $6 |
2017: 36 drugs
| Lyrica | 13 | $10,094 | $776 |
| Novolog Flexpen | 11 | $5,848 | $532 |
| Combivent Respimat | 11 | $3,921 | $356 |
| Symbicort | 12 | $3,813 | $318 |
| Qvar | 14 | $2,953 | $211 |
| Celecoxib | 11 | $1,699 | $154 |
| Levothyroxine | 57 | $1,280 | $22 |
| Atorvastatin | 60 | $1,225 | $20 |
| Pravastatin | 26 | $1,080 | $42 |
| Ventolin Hfa | 14 | $855 | $61 |
| Oxybutynin Chloride Er | 16 | $827 | $52 |
| Fluticasone Propionate | 57 | $680 | $12 |
| Trazodone | 12 | $561 | $47 |
| Gabapentin | 50 | $538 | $11 |
| Hydrocodone-Acetaminophen | 19 | $513 | $27 |
| Amlodipine Besylate | 60 | $482 | $8 |
| Metformin | 29 | $420 | $14 |
| Pantoprazole | 23 | $318 | $14 |
| Simvastatin | 30 | $269 | $9 |
| Omeprazole | 21 | $259 | $12 |
| Hydrochlorothiazide | 52 | $257 | $5 |
| Losartan | 31 | $240 | $8 |
| Ranitidine | 17 | $226 | $13 |
| Baclofen | 11 | $200 | $18 |
| Lisinopril | 29 | $192 | $7 |
| Fluoxetine | 20 | $191 | $10 |
| Pen Needles | 12 | $188 | $16 |
| Sertraline | 21 | $180 | $9 |
| Clonazepam | 19 | $176 | $9 |
| Glipizide | 24 | $144 | $6 |
| Atenolol | 19 | $93 | $5 |
| Spironolactone | 11 | $89 | $8 |
| Allopurinol | 13 | $72 | $6 |
| Prednisone | 12 | $68 | $6 |
| Tramadol | 11 | $40 | $4 |
| Furosemide | 14 | $31 | $2 |
2016: 27 drugs
| Qvar | 15 | $2,673 | $178 |
| Hydrocodone-Acetaminophen | 40 | $1,383 | $35 |
| Bromocriptine Mesylate | 12 | $1,219 | $102 |
| Gabapentin | 66 | $1,058 | $16 |
| Olopatadine | 13 | $1,010 | $78 |
| Ventolin Hfa | 13 | $687 | $53 |
| Atorvastatin | 34 | $607 | $18 |
| Levothyroxine | 29 | $585 | $20 |
| Pantoprazole | 26 | $453 | $17 |
| Fluticasone Propionate | 47 | $428 | $9 |
| Amlodipine Besylate | 63 | $376 | $6 |
| Metformin | 40 | $376 | $9 |
| Omeprazole | 31 | $326 | $11 |
| Tamsulosin | 11 | $323 | $29 |
| Dicyclomine | 11 | $273 | $25 |
| Lisinopril | 36 | $268 | $7 |
| Losartan | 25 | $251 | $10 |
| Clopidogrel | 21 | $239 | $11 |
| Hydrochlorothiazide | 52 | $224 | $4 |
| Montelukast | 16 | $190 | $12 |
| Simvastatin | 18 | $183 | $10 |
| Glipizide | 22 | $157 | $7 |
| Clonazepam | 19 | $150 | $8 |
| Sertraline | 16 | $103 | $6 |
| Alendronate | 14 | $88 | $6 |
| Ibuprofen | 13 | $87 | $7 |
| Lorazepam | 12 | $51 | $4 |
2015: 19 drugs
| Neupro | 11 | $6,281 | $571 |
| Fentanyl | 15 | $1,426 | $95 |
| Proair Hfa | 19 | $1,114 | $59 |
| Hydrocodone-Acetaminophen | 32 | $726 | $23 |
| Gabapentin | 17 | $412 | $24 |
| Omeprazole | 17 | $311 | $18 |
| Fluticasone Propionate | 33 | $300 | $9 |
| Atorvastatin | 21 | $285 | $14 |
| Levothyroxine | 16 | $280 | $17 |
| Pravastatin | 12 | $278 | $23 |
| Hydrochlorothiazide | 30 | $206 | $7 |
| Montelukast | 12 | $147 | $12 |
| Lisinopril | 20 | $146 | $7 |
| Clopidogrel | 15 | $144 | $10 |
| Clonazepam | 13 | $88 | $7 |
| Metformin | 12 | $87 | $7 |
| Amlodipine Besylate | 19 | $72 | $4 |
| Diazepam | 11 | $56 | $5 |
| Metoprolol | 11 | $34 | $3 |
2014: 8 drugs
| Levothyroxine | 21 | $361 | $17 |
| Hydrocodone-Acetaminophen | 20 | $345 | $17 |
| Lisinopril | 29 | $194 | $7 |
| Fluticasone Propionate | 11 | $183 | $17 |
| Gabapentin | 12 | $162 | $13 |
| Amlodipine Besylate | 24 | $144 | $6 |
| Hydrochlorothiazide | 14 | $120 | $9 |
| Metformin | 16 | $105 | $7 |
2013: 11 drugs
| Lantus | 19 | $5,512 | $290 |
| Omeprazole | 17 | $239 | $14 |
| Hydrocodone-Acetaminophen | 21 | $229 | $11 |
| Sertraline | 24 | $221 | $9 |
| Amlodipine Besylate | 29 | $210 | $7 |
| Benazepril | 22 | $167 | $8 |
| Hydrochlorothiazide | 27 | $113 | $4 |
| Lisinopril | 17 | $103 | $6 |
| Metformin | 11 | $86 | $8 |
| Simvastatin | 12 | $83 | $7 |
| Oxycodone-Acetaminophen | 12 | $77 | $6 |
Professional record
- NPI
- 1720350911
- Licence
- CA A119692California A119692: Current · expires 2027-12-31
- Trained
- Mayo Medical School, 2010
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Family medicine (207Q00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2012-02-02
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 211 Quarry Rd, Palo Alto, CA, 94304